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Summary 
The activation requirements for the generation of CD8 § cytotoxic T  cells (CTL) are poorly 
understood. Here we demonstrate that in the absence of exogenous help, a CD28-B7 interaction 
is necessary and sufficient for generation of class I major histocompatibility complex-specific 
CTL. Costimulation is required only during the inductive phase of the response, and not during 
the effector phase.  Transfection of the CD28 counter receptor, B7, into nonstimulatory P815 
cells confers the ability to elicit P815-specific CTL, and this response can be inhibited by anti- 
CD28 Fab or by the chimeric B7-binding protein CTLA4Ig. Anti-CD28 monoclonal antibody 
(mAb) can provide a costimulatory signal to CD8 + T  cells when the costimulatory capacity 
of splenic stimulators is destroyed by chemical fixation. CD28-mediated signaling provokes the 
release of interleukin 2 (IL-2) from the CD8 + CTL precursors, as anti-CD28  mAb could be 
substituted for by the addition of IL-2, and an anti-IL-2 mAb can block the generation of anti- 
CD28-induced CTL. CD4 + cells are not involved in the costimulatory response in the systems 
examined. We conclude that CD8 + T  cell activation requires two signals:  an antigen-specific 
signal mediated by the T  cell receptor, and an additional antigen nonspecific signal provided 
via a CD28-B7  interaction. 
N 
'aive CD4 + T cells and Thl clones require two signals 
for full activation: an antigen-specific signal via the an- 
tigen receptor and a second signal via an antigen nonspecific 
costimulatory receptor (1-3). In the absence of the costimula- 
tory signal, naive T cells exhibit suboptimal proliferation and 
cytokine secretion (4). It has been demonstrated recently that 
the costimulatory signal can be mediated by an interaction 
between the T cell surface molecule CD28 and its ligand B7 
(5-8). 
The activation requirements for naive CD8 + cells in the 
generation of an MHC class I-restricted response are less well 
understood. It has been suggested that generation of CD8 § 
CTL requires interaction with class II-restricted Th cells (9, 
10), and that when TCR affinity is low, CD4 +-mediated T 
cell help is required in vivo (11). Recent evidence indicates 
that although exogenous help from CD4 + Th in the form 
of IL-2 may enhance CTL responses by expansion of acti- 
vated precursors, this exogenous help is not always obliga- 
tory. In vitro studies have demonstrated that CD8 § cells can 
be stimulated to proliferate and generate CTL responses to 
alloantigens  in  the  absence  of CD4 +  Th  cells  (12-16). 
Moreover,  it  has  been demonstrated  that  mice in  which 
CD4 § cells have been eliminated by disruption of the CD4 
gene by homologous recombination can nonetheless mount 
an effective CTL response to viral challenge (17). 
Although it has been previously suggested that two signals 
might be required for an effective CTL response (18), there 
is at present little direct data concerning the role ofcostimula- 
tory signals.  The likelihood that costimulation is involved 
was suggested by the observation that the addition of acces- 
sory cells,  in the form of class II + cells,  adherent cells,  or 
macrophage cell lines was necessary for a primary CD8 + re- 
sponse in the absence of CD4 + cells (12,  13). In addition, 
cloned macrophage lines  (15) and dendritic cells  (14) can 
directly  activate  CD8 +  T  cells.  Whereas  B7  has  been 
demonstrated to be present on macrophages and dendritic 
cells (19, 20), its direct involvement in providing costimula- 
tory signals  to CD8 + T  cells has not been demonstrated. 
Recently, it has been shown that B7 transfected-ceUs  elicit 
potent protective immune responses even in the absence of 
CD4 §  T  cells (21,  22). 
Here we examine the role that  CD28  and  its  counter 
receptor, B7, play in the generation of primary responses in 
two class I-specific allogeneic responses in vitro: H-2  b anti- 
H-2  bm-1 and H-2  k or H-2  b anti-H-2 a. We demonstrate that 
cytotoxic responses to nonstimulatory P815 mastocytoma cells 
can be induced by B7-transfected P815  cells,  and that  the 
costimulatory signal can be blocked by Fab fragments of anti- 
CD28  antibody or by the chimeric B7 ligand CTLA4Ig. 
CD8 + T  cells can mature to CTL in the absence of CD4 § 
helper cells. Splenic stimulator cells express an essential fixation- 
labile signal that can be replaced by anti-CD28 antibody. We 
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a function of IL-2 secretion by the responding ceils. Finally, 
we demonstrate that whereas CD28-B7 interactions are re- 
quired for the induction phase of the response, they are not 
necessary during  the  effector phase. 
Table  1.  Coculture with B7-transfected, MHC Class I Allogeneic 
Stimulators Specifically Enriches for CD8 + T  Cells 
Yield 
Cells  Percent 
recovered  CD4/CD8  CD4  CD8 
Materials and Methods 
Cells and Cell Lines.  C3H/HeN  (H-2  k) mice were obtained 
from Charles River Laboratories (Wilmington, MA). C57B1/6 (H- 
2  b)  and  B6.CH-2  bmq  (H-2  bin-l) mice  were  obtained  from  the 
Jackson Laboratory (Bar Harbor, ME). LN T ceils were prepared 
by treatment of total LN calls with anti-MHC class II mAb con- 
taining supernatants and a mixture of rabbit (Cedarlane, Homby, 
Ontario, Canada) and guinea pig (Gibco, Grand Island, NY) com- 
plement. Negative selection for residual class II + B cells was ac- 
complished by panning on anti-mouse Ig coated plates. Occasion- 
ally, LN cells were passed over nylon wool before complement lysis. 
Both procedures resulted in >90%  T  cells.  CD8 + T  cells were 
prepared from LN T cells by incubation with anti-CD4 mAb fol- 
lowed by complement lysis or panning on anti-rat Ig coated plates. 
These populations were enriched to >85% CD8 +. The remaining 
cells were <0.5% CD4 + . 1-ethyl-3-(3-dimethylaminopropyl) car- 
bodiimide.HC1 (ECDI)-fixed splenocytes were prepared in 75 mM 
ECDI as described (23). MC201A5, p815 transfected with the mouse 
B7 gene (BT-P815),  was provided by Dr. L. Lanier (DNAX, Palo 
Alto, CA) (24).  Nontransfected P815 and B7-P815 were cultured 
in  10%  FCS-supplemented RPMI  1640 containing 2-ME,  gen- 
tamycin, pyruvate, glutamine, and Hepes (complete medium). Tram- 
fectants were checked periodically for B7 expression during  the 
course of these experiments by flow cytometry using CTLA4Ig. 
Reagents.  CTLA4Ig (25) was a gift of Dr. P. Linsley (Bristol- 
Myers Squibb  Pharmaceutical Research Institute,  Seattle,  WA). 
Anti-Ib2 mAb was used as a culture supernatant from $4B6 hy- 
bridoma cells, or purchased from PharMingen (San Diego, CA). 
Anti-CD28 mAb (26) was purified from ascites fluid from the hy- 
bridoma 37.51.  Fab fragments of anti-CD28 and F560.31,  a ham- 
ster IgG control antibody, were prepared by proteolysis with im- 
mobilized  papain  (Pierce  Chemical  Co.,  Rockford,  IL),  and 
undigested antibody removed by adsorption on protein A-Sepharose. 
Generation of Cytotoxic Cells.  LN or CD8 + T cells at 5  x  106 
per ml were cocultured with stimulator cells in complete medium 
at  37~  in  5%  CO2  for 5  d.  Stimulator  ceils  were irradiated 
splenocytes at a 2:1 stimulator/responder ratio, ECDI-fixed spleno- 
cytes at a 3-5:1 ratio, or irradiated p815 or B7-P815 at a 1:5 ratio. 
Before some assays, viable cells were purified by centrifugation over 
Histopaque (5  =  1.119; Sigma, St. Louis, MO), in which case cyto- 
toxic capacity was reported as E/T ratios. When cultures were tested 
for cytotoxicity without repurifying effector cells, cytotoxicity was 
reported as input to target ratios. Effector T ceils were not repurified 
when cultures yielded few viable cells, such as mixed lymphocyte 
culture (MLC) with ECDI-fixed targets, which had an average yield 
of 2% viable cells over five experiments. Cytotoxicity assay targets 
were either splenic LPS blasts or transformed cell lines. Target blasts 
were fractionated over Histopaque (/~  =  1.077;  Sigma), then la- 
baled by incubation with 300 mCi slCr for 90 rain. Transformed 
cell line targets were labeled directly without activation for 60 min. 
Dilutions of effector cells were prepared in complete medium, and 
SaCr-labeled cells were added at 104 per well for transformed cell 
line targets, and 2  x  l& per well for LPS blast targets to a final 
volume of 200/zl per well. Assays were incubated at 37~  for 4 h. 
100/~1  of culture supernatant  from each well was removed and 
processed for the calculation of specific SaCr release. 
x  l&  %  x  106 
Input LN T  13  68/26  8.8  3.4 
LN T  cocultured  with 
P815  5.5  66/22  3.6  1.4 
B7-P815  9.1  30/63  2.7  5.7 
LN T cells from C3H/HeN mice were cocultured with P815 or B7-P815 
as described. Viable cells were isolated. Numbers of CD4 + and CD8 + 
cells were determined using two-color flow cytometric analyses. The per- 
centages of CD4 + and CD8 + T cells in the input population were de- 
termined on day 0 of culture. 
Results and Discussion 
To directly assess the role of B7 in the cytotoxic response, 
we compared the capacity of P815 mastocytoma cells (H-2  d, 
MHC  class  II-)  and  B7-transfected  P815  cells  to  elicit 
specific CTL  from C3H  T  cells  (H-2  k) in  a  MLC.  CD8 + 
cells selectively proliferated in MLC with B7-P815,  whereas 
P815  MLC fielded many fewer cells and a CD4/CD8  ratio 
similar to the input  population  (Table  1).  Consistent  with 
the above result, little anti-PSI5 cytotoxic activity was elicited 
in control P815 MLC, whereas B7-P815  stimulators elicited 
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Figure  1.  B7 expression on stimulator cells allows induction of class 
I anti-aUogeneic  cytotoxicity,  but is not required for effector  function. C3H 
LN T cells were cocultured with I)815 or B7-P815 as described in Materials 
and Methods. Viable effector T cells were purified from MLC and tested 
for cytotoxicity against both P815 and B7-P815. (11, F-l) cytotoxic ac- 
tivity of T celts stimulated with P815 cells; (e, O, ) those stimulated 
with BT-P815. (11, e) B7-P815 targets; (I-7, O) P815 targets. This ex- 
periment has been performed six times with similar results. 
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Figure 2.  Generation  of CTL requires a CD28-B7 interaction, or IL-2. (A) CTLA4Ig blocks the induction ofcytotoxicity  against murine B7-transfected 
P815. Viable C3H-derived effector  T cells were purified from MLC. ([-]) Positive control cytotoxicity generated by C3H T cells in MLC with B7-P815. 
CTLA41g was included in MI.C at 5 #g/ml (A) and 25 #g/ml (A). Control culture cytotoxicity against self-blasts was 7% at an E/T of 30. (B) 
Anti-CD28 Fab fragment blocks the induction of cytotoxicity against murine B7-transfected P815 stimulators. (D) Control cytotoxicity generated 
by C3H T cells in MLC with B7-P815. Both the control F560.31 Fab (I) and anti-CD28 Fab (0) were included in MLC at 50 #g/ml. MIX2  containing 
anti-CD28 Fab yielded only enough viable cells upon repurification to perform titrations to an E/T of 10. Control culture cytotoxidty against EL-4 
targets was 5% at an E/T of 15. (C') Anti-Ib2 mAb blocks the induction of CTL against murine B7-transfected P815. ([[]) Control cytotoxicity 
generated by C3H T cells in MLC with B7-P815. Anti-IL-2 supernatant ($4B6) at 10% (0) and 5% (O) in MI.C. 25% F560.31 supernatant was 
used as a control (11). All targets were P815. Control culture cytotoxicity against third-party E1r  cells was 15% at an E/T of 20. (/9) Purified CD8 + 
T cells can generate CTL in MI.C with B7-P815. C57B1/6 CD8 + T cells were cocultured with B7-P815 (F-l), B7-P815 plus 70 #g/ml anti-CD28 
Fab fragments (I), or B7-P815 plus 20 #g/ml purified anti-IL-2  (0), then were tested for cytotoxicity against P815 targets. Anti-CD28 Fab was not 
nonspecifically reducing responses in these cultures, as the inclusion of II.-2  in Fab containing cultures restored cytotoxicity to control levels in related 
experiments (data not shown). (x axis) MLC input to assay target ratios (IT). MLC with P815 as stimulators generated no specific cytotoxicity against 
P815 targets at an I/T of 100, similarly to the data presented in Figure 1. 
a potent CTL response (Fig.  1).  This response was specific, 
since there was no significant cytolysis of L cells (H-2k), B7- 
transfected  L  cells,  or EL-4 (H-2  b) cells  (data not  shown). 
CTL from the B7-P815 cultures were equally effective in lysing 
B7-P815 and P815 (Fig.  1), confirming previous data which 
showed that  the expression of B7 by the  target cell is not 
essential  for effector function of the  CTL (24). 
Blocking experiments also demonstrated the importance 
of CD28-B7 interactions in the generation of CTL activity. 
It has been demonstrated that CTLA4Ig, a chimeric protein 
composed of the extracellular domain of CTLA-4 fused to 
human IgG C'y1 binds to the CD28 ligand B7 with high 
affinity (25).  We assessed the effect of CTLA4Ig on the re- 
sponse of T  cells to B7-P815 stimulators.  As shown in Fig. 
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CTL in a dose-dependent manner. Similarly, blockade of CD28 
on the responding T cells with nonstimulatory Fab fragments 
of anti-CD28 antibody also inhibited the generation of CTL 
(Fig.  2 B). 
Since it has been demonstrated that a major effect of CD28 
costimulation on CD4 + Thl cells is to enhance the secre- 
tion of IL-2, we sought to determine the role of IL-2 in the 
CTL costimulatory response. The addition of anti-IL-2 during 
the induction phase prevents the generation of CTL to B7- 
P815 (Fig.  2 C). Direct assays of IL-2 in MLC supernatants 
indicated the presence of only very low levels, perhaps as a 
consequence of low production and rapid consumption by 
the responding CD8 + cells (13). 
Although it seemed unlikely that CD4 + cells play a role 
in these CTL responses,  as there was selective proliferation 
of CD8 + (Table 1), the possibility of involvement of CD4 + 
T cell help could not be ruled out. Presentation of allogeneic 
class I molecule-derived peptides could have occurred by re- 
sidual APC in the responder T cell preparation, or as a result 
of upregulation of class II on P815 by cytokines secreted by 
activated T ceils (27). Therefore, we examined the ability of 
purified CD8 + T cells to generate CTL in MLC with P815 
and B7-P815  stimulators.  As shown in Fig.  2 D,  purified 
CD8 + T cells were capable of potent cytotoxic activity after 
coculture with B7-P815 but not P815.  Similarly to unffac- 
tionated T ceils, anti-CD28 Fab fragments and anti-IL-2 an- 
tibodies inhibited CTL generation. 
Whereas these results clearly demonstrate that B7 trans- 
fection renders p815 capable of inducing antigen-specific CTL 
in vitro,  the contribution of B7/CD28-mediated adhesion 
versus signaling was unclear. It has been demonstrated that 
chemical fixation destroys the ability of antigen-pulsed APC 
to stimulate IL-2 production and proliferation of CD4 + T 
cells (23).  This stimulation can be restored by the addition 
of allogeneic B cells or anti-CD28, indicating that fixation 
destroys costimulatory activity of the APC, while preserving 
the antigen signal (1, 3). This data also indicates that ECDI- 
fixed APC are capable of cognate interactions with T  cells, 
suggesting that necessary adhesion interactions (28) are not 
significantly affected by ECDI treatment. We therefore tested 
the signaling versus adhesion component of the CD28 inter- 
action using ECDI-fixed stimulator cells. The CTL response 
of C57B1/6 T cells to H-2  b~q splenocytes can be blocked by 
CTLA4Ig, indicating that a B7 interaction is necessary for 
induction of CTL (Fig.  3 A).  As shown in Fig.  3 B,  un- 
treated H-2  bml splenocytes also elicit H-2bml-specific  CTL 
from purified CD8 + T  cells. MLC containing ECDI-fixed 
H-2  bm-I stimulator cells yielded few viable cells after 5 d (av- 
erage 2% of control unfixed stimulators in five experiments), 
and cultures did not yield cells capable  of target cell lysis. 
Inclusion of anti-CD28 mAb in an MLC with ECDI-fixed 
H-2  bin-1 splenocyte stimulators resulted in the generation of 
antigen-specific CTL,  confirming that ECDI  destroys the 
costimulatory signal but not the specific antigen signal. Since 
soluble anti-CD28 contributes to the induction of CTL, but 
not to adhesion, the role of CD28 in these experiments is 
to provide a costimulatory signal rather than to stabilize the 
T  cell-APC interaction. 
The addition of 50 U/ml of IL-2 to the induction cultures 
with ECDI-fixed stimulators also restored the generation of 
specific CTL (Fig. 3 C). Cytotoxic activity was more potent 
in cultures containing exogenous IL-2, indicating that IL-2 
is limiting in control cultures. The generation of CTL in 
MLC with fixed stimulators and anti-CD28 could be blocked 
by the presence of anti-IL-2 mAb (Fig. 3 D). This is consis- 
tent with the data in Fig. 2 C, and suggests that CD28 sig- 
naling affects IL-2 secretion from CD8 + T  cells. Prolifera- 
tion and cytotoxic capacity of antigen and IL-2-stimulated 
cytotoxic cells is consistent with the differentiation and matu- 
ration scheme whereby activation of the TCR leads  to the 
onset of an IL-2-responsive state that in turn results in ma- 
ture cytotoxic cells. It is unknown if IL-2 is the only cytokine 
required, or if IL-2 signaling results in the secretion of other 
factors necessary for the complete maturation of cytotoxic 
potential (29). 
Cloned CTL exhibit an ability to kill targets in the ab- 
sence of costimulation, meanwhile becoming anergic in terms 
of IL-2 production (30).  This split  tolerance suggests that 
the signaling pathways for cytotoxicity and IL-2 secretion 
are distinct in terminally differentiated cells. This is confirmed 
by the results published elsewhere (24)  and herein (Fig.  1) 
indicating that activated CTL no longer require a CD28 in- 
teraction to kill once they have matured. This also suggests 
that naive T cells require a CD28-B7 interaction to induce 
differentiation to a mature cytolytic phenotype, and that this 
differentiative event leads to the distinct signaling pathways 
for proliferation and cytolysis. Interestingly, a CD28-B7 cell 
surface interaction was found to be necessary in humans for 
CD3-redirected lysis by small resting T  cells bearing the 
CD45RO + marker for memory cells (24). Memory cells re- 
tain their cytolytic phenotype as redirected lysis occurs within 
4 h. This is further evidence of distinct signaling pathways 
for lysis and proliferation in mature cells. However, unlike 
activated CTL, memory cells require the presence of B7 on 
the surface of target cells. Memory cells may therefore repre- 
sent a final differentiation of T cells, such that lysis of targets 
is again under the control of the tissue-specific  regulation 
of a concomitant CD28-B7  interaction. 
Recently, we and others (21, 22) have demonstrated that 
B7 transfection of nonimmunogenic tumors renders them 
susceptible to rejection. Rejection of B7-transfected tumors 
results in antigen-specific protection from subsequent tumor 
challenge. In addition,  abrogation of CD4 + T  cells in the 
tumor hosts had no effect on tumor rejection in the primary 
responses.  Therefore,  it  is  likely that  CD8 +  T  cells  can 
directly mount cytolytic responses in the absence of CD4 + 
Th cells if precursor CD8 + T  cells encounter antigen and 
B7 on stimulator cells in vivo, as described herein. 
Taken together, the results presented here indicate that a 
CD28-B7 signaling event is necessary for the generation of 
CTL in the absence of exogenous help. The CD28-B7 inter- 
action results  in  the secretion of IL-2 by CD8 + T  cells, 
which allows for the proliferation of antigen-specific CTL. 
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Figure  3.  A fixation-labile signal is necessary for induction of CTL against H-2  smq and can be substituted  for by anti-CD28 or II.-2. (A) CTLA4Ig 
blocks the induction of cytotoxicity by C57B1/6 LN T cells against H-2  smq stimulators.  C57B1/6 LN T cells were cocuhured with H-2  bmq stimulators 
in complete medium (I-3), with 10 gg/ml CTLA41g (1)  or 0.1 gg/ml CTLA4Ig (e). Viable effector T  cells were purified.  Targets were H-2  smq 
splenic blasts. No cytotoxicity was observed against  self-blasts (data not shown).  (B) Anti-CD28 mAb at 10 #g/ml restores the induction of specific 
cytotoxicity by C57B1/6  CD8 + T cells to ECDI-treated stimulator H-2  smq cells. CDS+ C57B1/6  T cells were cocuhured with H-2  bmq stimulators 
(D), with ECDI-fixed stimulators  (e), or with ECDI-fixed H-2  bmq stimulators  and  10 gg/ml anti-CD28 mAb (O). Targets were H-2  bin1 splenic 
blasts. (x-axis) MLC input to assay target ratios (IT).  Cytotoxicity against  third-party BALB/c and self-splenic targets  at an I/T of 80 were 9 and 
5%, respectively. This experiment  has been performed six times with similar results. (C) IL-2 induces H-2Sm'Lspecific  CTL against ECDI-fixed stimu- 
lators. C57B1/6  CD8 + T cells were cocultured  with H-2  bin'1 stimulators  (D), with ECDI-fixed stimulators  (e), or ECDI-fixed H-2  sin1 stimulators 
and 50 U/ml II:2 (O). Targets were H-2  bm'l splenic blasts. Positive control cultures  exhibited  no specific cytotoxicity against self-blasts at an I/T of 
100. In cultures  with IL2, 2% cytotoxicity was seen to self-targets  at an I/T ratio of 100. This experiment  has been performed three times with 
similar results.  (D) Anti-CD28-mediated induction of CTL to fixed H-2  bm'l stimulators  can be blocked by anti-IL2 mAb. C57B1/6  CD8 + T  cells 
were cocuhured with ECDI-fixed stimulators  (1); ECDl-fixed H-2  ~q stimulators  and 10/tg/ml anti-CD28 mAb (O), or ECDI-fixed stimulators, 
10/~g/ml anti-CD28, and 10%  anti-IL-2 supernatant  (e). Cytotoxicity against self- and third-party targets was <2% at an I/T of 40 for all groups. 
This experiment has been  performed  three times with similar results. 
TCR stimulation and IL-2 are the minimum requirements 
for the generation of cytotoxic T  cells in vitro. CD4 + Th 
cells are not necessary, but may serve to amplify the response 
when activated to secrete IL-2. 
This work was supported in part by a grant from the Irvington Institute for Medical Research (F. A. 
Harding)  and National  Institutes  of Health grant CA-40041 (J. P. Allison). 
1795  Harding and Allison  Brief Definitive Report Address correspondence to Dr. James E  Allison, Department of Molecular and Cell Biology, 401 LSA, 
University of California, Berkeley, Berkeley, CA 94720. 
Received for publication 20 October 1992 and in revised form  15 March  1993. 
R~ferences 
1.  Harding, F., J.G. McArthur, J.A. Gross, D.H. Raulet, andJ.P. 
Allison. 1992. CD28 mediated signalling costimulates murine 
T cells and prevents the induction of anergy in T cell dories. 
Nature (Lond.). 356:607. 
2.  Williams,  I.K., and E.K. Unanue.  1990. Costimulatory re- 
quirements of murine Thl clones. The role of accessory cell- 
derived signals in responses to anti-CD3 antibody.J. Immunol. 
145:85. 
3. Jenkins, M.K., J.D. Ashwell,  and R.H. Schwartz. 1988. A1- 
logeneic non-T spleen cells restore the responsiveness of normal 
T cell clones stimulated with antigen and chemically modified 
antigen-presenting cells. J. Immunol. 140:3324. 
4.  Thompson, C.B., T. Lindsten, J.A. Ledbetter, S.L. Kunkel, 
H.A. Young, S.G. Emerson, J.M. Leiden, and C.H. June. 1989. 
CD28 activation pathway regulates the production of multiple 
T-cell-derived lymphokines/cytokines. Proc. Natl.  Acad. Sci. 
USA.  86:1333. 
5.  Linsley, P.S., W. Brady, L. Grosmaire, A. Aruffo, N.K. Damle, 
and J.A. Ledbetter. 1991. Binding of the B cell activation an- 
tigen B7 to CD28 costimulates T cell proliferation and inter- 
leukin 2 mRNA accumulation. J. Exp. Med. 173:721. 
6.  Koulova, L., E.A. Clark, G. Shu, and B. Dupont. 1991. The 
CD28 ligand B7/BB1 provides costimulatory signal for aUoac- 
tivation of CD4 + T cells. J. Exl~ Med. 173:759. 
7.  Linsley, P.S., E.A. Clark, andJ.A. Ledbetter. 1990. The T cell 
antigen, CD28, mediates adhesion with B cells by interacting 
with the activation antigen, B7/BB-1. Proc. Natl. Acad. Sci. 
USA.  87:5031. 
8.  Reiser,  H.,  G.J.  Freeman,  Z.  Razi-Wolf,  C.D.  Gimmi,  B. 
Benacerraf,  and L.M. Nadler.  1992. Murine B7 antigen pro- 
vides an ef~cient costimulatory signal for activation of murine 
T lymphocytes via the T-cell receptor/CD3 complex. Proa Natl. 
Acad. Sci. USA.  89:271. 
9.  yon Boehmer, H., and W. Haas.  1979. Distinct Ir genes for 
helper and killer cells in the cytotoxic response to H-Y antigen. 
J. Extx Med. 150:1134. 
10.  Keene, J., andJ. Forman. 1982. Helper activity is required for 
the in vivo generation ofcytotoxic T lymphocytes.J. Extx Med. 
155:768. 
11.  Gao, X.-M., B. Zheng, F.Y. Liew, S. Brett, andJ. Tite. 1991. 
Priming of influenza virus-specific cytotoxic T  lymphocytes 
in vivo by short synthetic peptides. J. Immunol. 147:3268. 
12.  Sprent, J., and M. Schaefer. 1985. Properties of purified T cell 
subsets. I. In vitro responses to class I vs. class II H-2 antigens. 
J. ExI~ Med. 162:2068. 
13.  Mizuochi, T., S. Ono, T.R. Malek, and A. Singer. 1985. Char- 
acterization of two distinct primary T  cell populations that 
secrete interleukin 2 upon recognition of class I or class II major 
histocompatibility antigens. J. Extx Med. 163:603. 
14.  Young, J.W., and K.M. Steinman. 1990. Dendritic cells stimu- 
late primary human cytolytic lymphocyte responses in the ab- 
sence of CD4 + helper T  cells. J. Exp. Med. 171:1315. 
15.  McCormack, J.M., D. Sun, and W.S. Walker. 1991. A subset 
of mouse splenic macrophages can constitutively present al- 
loantigen directly to CD8 + T  cells. J. Immunol. 147:421. 
16.  Inaba, K., J.W. Young, and R..M. Steinman. 1987. Direct ac- 
tivation of CD8 + cytotoxic T lymphocytes by dendritic calls. 
J. Ex  F  Med. 166:182. 
17.  Rahemtulla,  A.,  W.E  Fung-Leung, M.W. Schillham,  T.M. 
Kundig, S.R. Sambhara, A. Narendran, A. Arabian, A. Wake- 
ham, C.G.  Paige, IL.M.  Zinkernagel, R.G. Miller,  and T.W. 
Mak. 1991. Normal development and function of CD8 + cells 
but markedly decreased helper cell activity in mice lacking CD4. 
Nature (Lond). 353:180. 
18.  Lafferty, K.J., L. Andrus, and S.J. Prowse. 1980. Role oflym- 
phokine and antigen in the control of specific T cell responses. 
Immunol. Rev. 51:279. 
19.  Razi-Wolf, Z., G.J. Freeman, F. Galvin, B. Benacerraf, L. Na- 
dler, and H. Reiser. 1992. Expression and function of the mu- 
fine B7 antigen, the major costimulatory molecule expressed 
by peritoneal exudate cells. Proa Natl. Acad. Sci. USA. 89:4210. 
20.  Larsen, C.P., S.C. Ritchie, T.C. Pearson, P.S. Linsley, and R.P. 
Lowry. 1992. Functional expression of the costimulatory mol- 
ecule, B7/BB1, on murine dendritic cell populations. J. Exp. 
Med. 176:1215. 
21.  Townsend, S.E., andJ.P. Allison. 1993. Tumor rejection after 
direct costimulation of CD8 + T cells by B7-transfected  mela- 
noma cells. Science (Wash. DC).  259:368. 
22.  Chen, L., S. Ashe, W.A. Brady, I. HeUstrom, K.E. Hellstrom, 
J.A. Ledbetter, P. McGowan, and P.S. Linsley. 1993. Costimu- 
lation of antitumor immunity by the B7 counterreceptor or 
the T lymphocyte molecules CD28 and CTLA4. Cell. 71:1093. 
23. Jenkins, M.K., and R.H. Schwartz. 1987. Antigen presenta- 
tion by chemically modified splenocytes induces antigen-specific 
T  cell unresponsiveness  in  vitro and in  vivo. j.  Exp.  Med. 
165:302. 
24.  Azuma, M., M. Cayabyab, D. Buck, J.H. Phillips,  and L.L. 
Lanier. 1992. CD28 interaction with B7 costimulates primary 
allogeneic proliferative responses and cytotoxicity mediated by 
small,  resting T  lymphocytes. J. Exl~ Med. 175:353. 
25.  Linsley, P.S., W. Brady, M. Umes, L.S. Grosmaire, N.K. Darrfle, 
and J.A. Ledbetter. 1991. CTLA-4 is a second receptor for the 
B cell activation antigen B7. J. Ext2 Med. 174:561. 
26.  Gross, J.A., E. Callas,  and J.E  Allison.  1992. Identification 
and distribution of the costimulatory receptor CD28 in the 
mouse. J. Immunot. 149:380. 
27.  Wong, G.H.W., I. Clark-Lewis, A.W. Harris, andJ.W. Schrader. 
1984. Effect of cloned interferon-',/on expression of H-2 and 
Ia antigens on cell lines on hemopoietic, lymphoid, epithelial, 
fibroblastic  and neuronal origin. Eur. j.  Immunol. 14:52. 
28.  Young, J.W., L.  Koulova, S.A.  Soergel, E.A.  Clark,  R.M. 
Steinman, and B. Dupont. 1992. The B7/BB-1 antigen pro- 
vides one of several costimulatory signals for the activation of 
CD4 + T lymphocytes by human blood dendritic cells in vitro. 
j.  Clin. Invest. 90:229. 
29.  Horohov, D.W., N.I. Stocks, andJ.E Siegel. 1988. Limiting- 
dilution analysis of human CTL differentiation. Requirement 
for a lymphokine-mediated differentiation signal. Immunology. 
65:119. 
30.  Otten,  G.lk.,  and  R.N.  Germain.  1991. Split  anergy in  a 
CD8 + T  cell: receptor-dependent cytolysis in the absence of 
interleukin-2 production. Science (Wash. DC). 251:1228. 
1796  CTL Induction Requires CD28-mediated Costimulation 